# Biomarker Core

> **NIH NIH P30** · CLEVELAND CLINIC LERNER COM-CWRU · 2020 · $291,002

## Abstract

BIOMARKER CORE
PROJECT SUMMARY
The mission of the Biomarker Core (BC) is to support Alzheimer's disease and Alzheimer's disease related
disorders (AD/ADRD) research projects by collecting, storing, tracking, sharing and analyzing biospecimens
and associated clinical, genetic, biomarker data. The collected clinical, genetic and biomarker data on a
variety of human biospecimens will contribute to the understanding of AD/ADRD heterogeneity by cataloging
the progression, onset and disease symptoms of patient biospecimens currently stored in Cleveland Clinic
Lou Ruvo Center for Brain Health (CCLRCBH) Aging and Neurodegenerative Disease Biobank (CCLRCBH-
Biobank) and future Cleveland Alzheimer's Disease Research Center (CADRC) collections. This information
will contribute to improving diagnosis in unique understudied populations as well as the population as a whole.
Toward this mission, we have previously established and integrated biospecimen collection and research
collaborations between Case Western Reserve University (CWRU), MetroHealth, University Hospitals (UH),
and the Cleveland Clinic Foundation (CCF). The aims of the BC are to; 1) Facilitate research by leveraging
and expanding our large existing CCLRCBH-Biobank infrastructure and biospecimens linked with subject clinical
data in the integrated database and continue to include longitudinal biospecimen collection. 2) Provide basic
biomarker characterization to facilitate AD/ADRD research, 3) Provide basic genetic information to facilitate
AD/ADRD research. 4) Distribute biospecimens to neurodegenerative disease consortiums and coordinating
centers as well as to internal and external investigators. To these aims, we have assembled a team of experts
that together will contribute to biospecimen collection for the CADRC. We anticipate that establishing CADRC
and BC will provide further essential infrastructure to facilitate and integrate the independent projects of
unique and understudied populations, such as African Americans as well as understudied neurodegenerative
disorders, including rapidly progressive AD, traumatic brain injury (professional fighters) and dementia with
Lewy bodies (DLB). Standard clinical data (the Uniform Data Set, or UDS) from these diverse understudied
populations will be linked with generated biomarker and genetic data. Genetic and biomarker data linked to
relevant clinical data in accordance with goals of the National Alzheimer's Project Act (NAPA) will be shared
with the scientific community including with the; Alzheimer's Disease Genetic Consortium (ADGC), National
Alzheimer's Coordinating Center (NACC), National Institute on Aging Genetics of Alzheimer's Disease Data
Storage (NIAGADS). The already established CCLRCBH-Biobank and highly trained personnel will insure
seamless creation of the CADRC BC and importantly facilitate future innovative AD/ADRD research projects
that will enhance our understanding of the heterogeneity of AD and ADRD pathology.

## Key facts

- **NIH application ID:** 9967977
- **Project number:** 5P30AG062428-02
- **Recipient organization:** CLEVELAND CLINIC LERNER COM-CWRU
- **Principal Investigator:** Lynn Bekris
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $291,002
- **Award type:** 5
- **Project period:** — → 2023-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9967977

## Citation

> US National Institutes of Health, RePORTER application 9967977, Biomarker Core (5P30AG062428-02). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9967977. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*